Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament ...

On Wednesday, Cantor Fitzgerald reaffirmed its positive stance on Novo Nordisk (NYSE:NVO), maintaining an Overweight rating and a price target of $160.00. The reaffirmation came as Novo Nordisk ...

He specializes in security and geopolitics in the Arctic and Baltic Sea regions, as well as large corporates such as obesity drug maker Novo Nordisk, brewer Carlsberg and shipping group Maersk.

NanoVation will receive $600m in upfront cash and potential milestone payments, as well as tiered royalties on future product sales.

Novo Nordisk A/S (NVO) has turned into one of the most valuable pharma companies in the world thanks to its success with weight loss drug Wegovy. But growth has recently slowed down, and the ...

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Novo Nordisk NVO in the last three months. The table below offers a condensed view of their ...

COPENHAGEN, Sept 11 (Reuters) - Novo Nordisk's highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early-stage trial, with mild-to-moderate side ...